Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Ballantyne

Showing results (11-20 of 113) with videos related to

Pageof 12
Sort By:
The American Journal of Cardiology|October 10, 1998
Clinical trial endpoints: angiograms, events, and plaque instabilityC M Ballantyne
International Journal of Clinical Practice. Supplement|September 26, 2002
Familial hypercholesterolaemia: optimum treatment strategiesC M Ballantyne
The American Journal of Managed Care|June 1, 2001
Surrogate endpoints and newer risk markers in atherosclerosis managementC M Ballantyne
The American Journal of Cardiology|February 17, 2001
Case 4: type 2 diabetes, hypertension, and dyslipidemiaC M Ballantyne
Clinical Cardiology|July 11, 2001
Treating mixed dyslipidemias: why and howC M Ballantyne
Journal of Cardiovascular Risk|December 29, 1998
Molecular markers for atherosclerosisC M Ballantyne, Y Abe
Current Cardiology Reports|September 12, 2000
Inflammation and lipid-lowering treatmentC M Ballantyne, Y Abe
Preventive Cardiology|February 6, 2002
The evolving role of high-density lipoprotein in reducing cardiovascular riskC M Ballantyne, G R Rangaraj
Circulation|June 13, 2001
In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is nowG C Fonarow, C M Ballantyne
The American Journal of Cardiology|March 1, 2000
Quality assessment and lipid management: considerations for computer databases for tracking patientsB C Short, C M Ballantyne
Pageof 12

Showing results (11-20 of 113) with videos related to

Sort By:
Pageof 12
The American Journal of Cardiology|October 10, 1998
Clinical trial endpoints: angiograms, events, and plaque instabilityC M Ballantyne
International Journal of Clinical Practice. Supplement|September 26, 2002
Familial hypercholesterolaemia: optimum treatment strategiesC M Ballantyne
The American Journal of Managed Care|June 1, 2001
Surrogate endpoints and newer risk markers in atherosclerosis managementC M Ballantyne
The American Journal of Cardiology|February 17, 2001
Case 4: type 2 diabetes, hypertension, and dyslipidemiaC M Ballantyne
Clinical Cardiology|July 11, 2001
Treating mixed dyslipidemias: why and howC M Ballantyne
Journal of Cardiovascular Risk|December 29, 1998
Molecular markers for atherosclerosisC M Ballantyne, Y Abe
Current Cardiology Reports|September 12, 2000
Inflammation and lipid-lowering treatmentC M Ballantyne, Y Abe
Preventive Cardiology|February 6, 2002
The evolving role of high-density lipoprotein in reducing cardiovascular riskC M Ballantyne, G R Rangaraj
Circulation|June 13, 2001
In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is nowG C Fonarow, C M Ballantyne
The American Journal of Cardiology|March 1, 2000
Quality assessment and lipid management: considerations for computer databases for tracking patientsB C Short, C M Ballantyne
Pageof 12